
C-Suite Perspectives
Welcome to C-Suite Perspectives, a podcast series by The Conference Board. Hosted by our President & CEO, Steve Odland, this weekly conversation will take an objective, data-driven look at a range of business topics aimed at executives. Listeners will come away with what The Conference Board does best: insights for what’s ahead™.
Show episodes
Find out how FIS is staying on the cutting edge of technology while serving clients and communities. FIS processes more than 10% of the global economy and handles $16 trillion in assets annually. How does the company simultaneously safeguard data, pursue innovation, and serve its communities? Join David Young and g
More C-Suite leaders view their boards as effective in 2025, but numerous challenges remain, including keeping up with AI. More than one-third (35%) of C-Suite executives surveyed by PwC and The Conference Board say their board’s effectiveness is “excellent” or “good.” What are these boards doing well, and where do
In this episode, we break down the latest data from The Conference Board Consumer Confidence Index®, released today. The numbers show a modest but notable improvement in consumer sentiment as we move through summer 2025. We explore: Overall Confidence Ticks Up: The Consumer Confidence Index rose by 2.0 points to 97.2,
Learn how Clorox invested in technological innovation so it could continue delivering superior consumer experiences. Almost 90% of US households use Clorox products, giving the company a unique window into consumer behavior during this uncertain time. How has The Clorox Company used innovation and technology to reinve
2025 is half over. What issues should human capital leaders focus onduring the restof the year? In this time of rapid change, chief HR officers (CHROs) shouldfocus on issues such as AI transformation, leadership resilience, and strategic workforce planning. Whatelse made The Conference Board’s top 10 CHRO prioritie
Learn why culture and constant innovation are essential to developing life-changing biopharma treatments. Vertex Pharmaceuticals focuses on “serial innovation” because this year’s billion-dollar blockbuster drug could become next year’s failure. How does this biopharmaceutical company recruit and onboard employees, and